A jump in earnings, the acquisition of Apton and the launch of the long-awaited Onso sequencing system – all in one week at Pacific Biosciences.

Restructuring Edition: FibroGen follows its clinical setback with a 32% reduction in force, cutting 104 jobs. Also, Amarin named a new CEO, but cut all US sales and 30% of non-sales US roles, and 9 Meters is headed for dissolution after Chapter 7 bankruptcy, while several others seek strategic alternatives.

PacBio has been burning through investors’ cash as it works to make long-read sequencing more accessible. Neil Ward, the company’s general manager, laid out his thoughts on the technology, its place in the market and how genomics data can be both effectively and fairly utilized.

Roughly $130m was raised in eight biopharma financings in China over the past months that were backed by venture capital investors.